Antitumor Activity of Liposomal Prednisolone Phosphate Depends on the Presence of Functional Tumor-Associated Macrophages in Tumor Tissue  by Banciu, Manuela et al.
Antitumor Activity of Liposomal
Prednisolone Phosphate Depends
on the Presence of Functional
Tumor-Associated Macrophages
in Tumor Tissue1
Manuela Banciu*,†, Josbert M. Metselaar*,
Raymond M. Schiffelers* and Gert Storm*
*Department of Pharmaceutics, Utrecht Institute for
Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht,
The Netherlands; †Department of Experimental Biology,
Faculty of Biology and Geology, “Babes-Bolyai” University,
Cluj-Napoca, Romania
Abstract
Prednisolone phosphate (PLP) encapsulated in long-circulating liposomes (LCLs) (LCL-PLP) exerts antitumor activity
through the inhibition of tumor angiogenesis. It is known that tumor-associated macrophages (TAMs) play a crucial
role in tumor growth as they are actively involved in promoting and maintaining tumor angiogenesis. To gain more
insight into the antiangiogenic mechanisms of LCL-PLP, this study aimed to investigate the role of TAM in the anti-
tumor mode of action of LCL-PLP in B16.F10 melanoma-bearing mice. Our results show that TAMs have a pivotal
function in the growth of B16.F10 melanoma through the production of pro-angiogenic/pro-inflammatory factors.
One of the major inhibitory actions of LCL-PLP on tumor growth is the reduction of the TAM-mediated production
of pro-angiogenic factors, whereas production of anti-angiogenic factors by these cells is hardly affected.
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Introduction
Prednisolone phosphate (PLP) encapsulated in long-circulating lipo-
somes (LCLs) (LCL-PLP) has been shown to exert strong inhibitory
effects on tumor growth in subcutaneous (s.c.) B16.F10 melanoma
and C26 colon carcinoma murine tumor models [1,2]. The antitu-
mor activity of the LCL-PLP formulation mediated by antiangio-
genic effects is enabled by the tumor-targeting property of the
liposomes. Site-specific delivery increases the intratumoral drug con-
centration and thereby intensifies the inhibitory effects of PLP [3].
The tumor-targeting capability of LCLs is the combined result of
their long circulation time and an enhanced permeability of tumor
vasculature, compared to healthy endothelium [1,4]. Long-circulating
liposomes can extravasate through the hyperpermeable pathologic vas-
culature and thereby accumulate in malignant tissue. This effect is re-
ferred to as the enhanced permeability and retention (EPR) effect [3].
Interestingly, LCLs localize in the immediate vicinity of tumor blood
vessels and can be visualized in the endosomal/lysosomal compartment
of tumor-associated macrophages (TAMs) [2]. Among the immune
cell populations present in tumor tissue, TAMs seem most important
in promoting and coordinating tumor growth [5]. Tumor-associated
macrophages are known to be an important source of inflammatory
and angiogenic factors involved in all steps in tumor angiogenesis
[4]. Therefore, to gain more insight into the antitumor mode of action
of LCL-PLP, this study aims to address the role of TAM in the anti-
tumor effect of LCL-PLP in the murine B16.F10 melanoma model.
Firstly, the ability of clodronate-containing liposomes to deplete mac-
rophages was used as a tool to evaluate whether TAMs play a pivotal
role in the growth of B16.F10 melanoma. Secondly, tumor-bearing an-
imals were pretreated with clodronate liposomes before the actual
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treatment with LCL-PLP to study the antitumor activity of LCL-PLP
toward tumors with suppressed TAM function. The effect of LCL-PLP
treatment on the levels of pro-angiogenic and anti-angiogenic factors was
determined in B16.F10 melanoma-bearing mice with and without pre-
treatment with liposomal clodronate (Lip-CLOD). To suppress TAM
functions in tumors, a mixture of two types of clodronate liposomes
was used: LCL-encapsulated clodronate to deplete TAM and large neg-
atively charged clodronate liposomes to prevent chemoattraction of new
monocytes from the bloodstream in the tumor tissue. Our results show
that LCL-PLP exert a strong suppressive effect on TAM as reflected by a
reduced production of pro-angiogenic factors by these cells.
Materials and Methods
Preparation of LCL-PLP
Long-circulating liposomes were prepared as described previously
[2]. In brief, appropriate amounts of dipalmitoylphosphatidylcholine
(Lipoid GmbH, Ludwigshafen, Germany), cholesterol (Sigma, St.
Louis, MO), and poly(ethylene glycol) 2000-distearoylphosphatidyl-
ethanolamine (Lipoid GmbH) in a molar ratio of 1.85:1.0:0.15, re-
spectively, were dissolved in ethanol in a round-bottom flask. After
lipid film formation, the film was hydrated with a solution of 100 mg/ml
PLP, (obtained from Bufa, Uitgeest, The Netherlands). Liposome
size was reduced by multiple extrusion steps through polycarbonate
membranes (Nuclepore, Pleasanton, CA) with a final pore size of
50 nm. The mean particle size of the liposomes was determined by dy-
namic light scattering and found to be 100 nm with a polydispersity
value lower than 0.1. The polydispersity values obtained indicate lim-
ited variation in particle size. Phospholipid content was determined
with a phosphate assay according to Rouser and Yamamoto [6]. Un-
encapsulated drug was removed by dialyzing in a Slide-A-Lyzer cassette
with a molecular weight cutoff of 10 kDa at 4°C with repeated
changes of buffer. Glucocorticoid phosphate content was assessed by
high-performance liquid chromatography as described previously [7].
The type of column was RP18 (5 μm) (Merck, Darmstadt, Germany)
and the mobile phase consisted of acetonitrile and water (1:3 v/v), pH 2.
The eluent was monitored with an ultraviolet detector set at 254 nm.
The detection limit for the high-performance liquid chromatography
setup was 20 ng/ml. The liposomal preparation contained about
5 mg PLP/ml and ∼60 μmol phospholipid/ml.
Preparation of LIP-CLOD
Clodronate-containing liposomes as macrophage-suppressive agents
have already been used in inflammatory and autoimmune diseases,
where macrophages have been suggested to be involved in pathologic
processes [8]. Previous studies demonstrated that macrophages were ef-
ficiently eliminated at 24 hours after intravenous (i.v.) administration
of a dose of 25 mg/kg of liposomal clodronate [9]. To deplete TAM,
clodronate-containing LCLs (mean size about 100 nm) were essentially
prepared as described above for LCL-PLP. After lipid film formation,
the film was hydrated with a 60 mg/ml solution of dichloromethylene
bisphosphonate, disodium clodronate (Bonefos infusion; Schering,
Weesp, The Netherlands). To reduce chemoattraction of new mono-
cytes in tumors, large negatively charged liposomes (mean size around
1 μm) were used as delivery systems for clodronate. For this reason,
appropriate amounts of egg phosphatidylcholine and egg phosphatidyl-
glycerol (both obtained from Lipoid GmbH) and cholesterol (Sigma) in
a ratio of 1.85:0.3:1 were dissolved in ethanol. The hydration of lipid
film was performed with 10 ml of Bonefos infusion. Liposomes were
extruded twice through a filter with a pore size of 8 μm. Phospholipid
content was determined with a phosphate assay according to Rouser
and Yamamoto [6]. Unencapsulated drug was removed by dialyzing in
a Slide-A-Lyzer cassette with a molecular weight cutoff of 10 kDa at 4°C
with repeated changes of buffer. The aqueous phase after extraction was
used for determining clodronate content by UV spectrophotometry at
238 nm after formation of clodronate complex with CuSO4 solution
[10]. Both types of liposomes contained about 5 mg clodronate/ml
and ∼70 μmol phospholipid/ml.
Cells
B16.F10 murine melanoma cells were cultured as monolayers at
37°C in a 5% CO2–containing humidified atmosphere in DMEM
medium (Gibco, Breda, The Netherlands) supplemented with 10%
(v/v) heat-inactivated fetal calf serum (Gibco), 100 IU/ml penicillin,
100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B (Gibco).
Murine Tumor Model
To exclude antitumoral effect of T cells [11], male Balb/c athymic
nude Foxn1nu−/nu− mice (6–8 weeks of age) were used. They were
obtained from Harlan (The Netherlands) and kept in standard hous-
ing under filter tops with standard rodent chow and water available
ad libitum, and a 12-hour light/dark cycle. Experiments were per-
formed according to the national regulations and were approved by
the local animal experiments ethical committee. For tumor induc-
tion, 1 × 106 B16.F10 melanoma cells were inoculated s.c. in the
right flank of mice. B16.F10 tumors became palpable at day 7 after
tumor cell inoculation.
Effects of Lip-CLOD on Tumor Growth
To determine whether TAMs play an important role in tumor
growth, B16.F10 melanoma-bearing athymic mice were injected i.v.
with a mixture of both types of clodronate liposomes (ratio 1:1(w/w))
(Lip-CLOD) at a dose of 25 mg/kg at day 7 (when tumors became
palpable). As control tumors, tumors from mice treated with PBS which
did not receive Lip-CLOD treatment were used. Five animals were used
per experimental group.
Effects of Pretreatment with Lip-CLOD on Antitumor Activity
of LCL-PLP
To compare the effects of LCL-PLP and free PLP on the growth of
the tumors in mice pretreated with Lip-CLOD and in mice when
Lip-CLOD pretreatment was not administered, LCL-PLP and free
PLP were injected i.v. at a dose of 20 mg/kg at day 8 after tumor
cell inoculation. To eliminate TAM functions in tumors, mice re-
ceived i.v. a dose of 25 mg/kg of Lip-CLOD at day 7 after tumor
cell inoculation. Controls received PBS or empty liposomes at day 8 af-
ter tumor cell inoculation. Five animals were used per experimental
group. Since day 7, tumor volume was measured regularly and cal-
culated according to the formula: V = 0.52 × a2 × b, where a is the
smallest and b is the largest superficial diameter (in mm). Mice were
sacrificed when the tumor volumes were larger than 2 cm3.
Effect of Lip-CLOD Pretreatment on TAM-Mediated
Production of Angiogenic Factors
To evaluate the role of TAM in intratumoral production of angio-
genic factors, mice received Lip-CLOD at a dose of 25 mg/kg, at
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day 7 after tumor cell inoculation. Controls received PBS. Four to five
animals were used per experimental group. On day 12, mice were sac-
rificed and tumors were isolated. A screening of angiogenic proteins
in tumor tissue was performed using an angiogenic protein array
(RayBiotech Inc., Norcross, GA) [12] for 24 proteins involved in
angiogenesis, inflammation and apoptosis as described previously
[1]. Each angiogenic protein for each experimental group was de-
termined in duplicate. Final results represent the mean ± SD of two
independent experiments.
Effect of Pretreatment with Lip-CLOD on Antiangiogenic
Activity of LCL-PLP
To compare the effects of LCL-PLP and free PLP on angiogenic
protein production in tumors from mice pretreated with Lip-CLOD
and from mice when Lip-CLOD pretreatment was not administered,
LCL-PLP and free PLP were injected i.v. at a dose of 20 mg/kg at
days 8 and 11 after tumor cell inoculation. To deplete TAM, mice re-
ceived i.v. Lip-CLOD at a dose of 25 mg/kg, at day 7 after tumor cell
inoculation. Controls received PBS or empty liposomes at days 8 and
11 after tumor cell inoculation. Four to five animals were used per
experimental group. On day 12, mice were sacrificed and tumors
were isolated. A screening of angiogenic proteins in tumor tissue
was performed as described previously [1]. Each angiogenic protein
for each experimental group was determined in duplicate. Final re-
sults represent mean ± SD of two independent experiments.
Immunohistochemical Examination of Tumor Tissue After
LCL-PLP Treatment
To evaluate the effects of (LCL-) PLP and Lip-CLOD on TAM in-
filtration in tumor tissue, we compared F4/80–stained sections.
LCL-PLP and free PLP were injected i.v. at a dose of 20 mg/kg at
day 8 after tumor cell inoculation. Tumor-bearing mice, in which
TAM were depleted, received i.v. a dose of 25 mg/kg of Lip-CLOD,
at day 7 after tumor cell inoculation. Two to three animals were used
per experimental group. Tumors were dissected 48 and 96 hours after
Lip-CLOD injection. Tumors were snap-frozen in liquid nitrogen for
immunohistochemical staining. Rat anti–mouse F4/80 antibody
(Serotec, Oxford, United Kingdom) was used as a primary antibody.
As a secondary antibody biotinylated rabbit anti–rat IgG (Vector Lab-
oratories, Burlingame, CA) was used. After incubation with HRP–
streptavidin (Vector Laboratories) and peroxidase substrate, slides were
counterstained in hematoxylin (Sigma-Aldrich Co., Zwijndrecht, The
Netherlands) and mounted in Kaiser’s glycerol-gelatin (Merck). All
slides were examined by light microscopy regarding TAM distribution
in tumor tissue.
Statistical Analysis
Data from different experiments were reported as mean ± SD. For
statistical analysis, Student’s t test for independent means was used. A
P value of < .05 was considered significant. To compare the effects of
different treatments on tumor growth in vivo, one-way ANOVA with
Dunnett multiple comparison test was used. The differences between
the effects of different treatments on angiogenic factor production
were analyzed by two-way ANOVA with Bonferroni correction for
multiple comparisons using GraphPad Prism version 4.02 for Win-
dows, GraphPad Software (San Diego, CA).
Results
Effect of Lip-CLOD on Tumor Growth
To determine whether TAM play a critical role in supporting tu-
mor growth, a mixture of two types of clodronate-containing lipo-
somes in a ratio of 1:1 (w/w) (Lip-CLOD) was injected i.v. at day 7
(when tumors became palpable), at a dose of 25 mg/kg. To deliver
clodronate to TAM, LCL (mean size about 100 nm) were used
[2,13]. In addition, to reduce chemoattraction of new monocytes in
tumors, clodronate-containing large negatively charged liposomes
(mean size about 1 μm) were coinjected [14]. Depletion of TAM in
tumor tissue was verified by immunohistochemical examination of tu-
mor tissue for the macrophage antigen F4/80, at 48 and 96 hours after
Lip-CLOD administration (Figure 1; Table 5). At 48 hours, without
Lip-CLOD treatment, TAM were observed at the rim of the control
tumors (i.e., tumors in mice treated only with PBS) (Figure 1B). At the
same time point, TAM were not noted in tumors from mice that re-
ceived treatment with Lip-CLOD (Figure 1A). At the 96-hour obser-
vation time point, TAMs were observed spread over the tumor tissue
in large areas in control tumors (Figure 1D). At the same time point,
after treatment with Lip-CLOD, tumors also contained TAM in large
areas but at a lower density compared to TAM in control tumors (Fig-
ure 1C; Table 5).
Interestingly, at day 14 after tumor cell inoculation (the day when
the first tumors from the control group reached a volume of 2 cm3),
tumor volume after Lip-CLOD was 55% smaller (P = .02) compared
to control tumors (Figure 2). This strong inhibitory effect on tumor
growth induced by Lip-CLOD demonstrates the pivotal role of TAM
in B16.F10 melanoma growth.
Effect of Pretreatment with Lip-CLOD on Antitumor Activity
of LCL-PLP
To determine whether the antitumor activity of LCL-PLP in the
B16.F10 melanoma model is dependent on the TAM functions in
tumor tissue, tumor-bearing mice were injected i.v. with LCL-PLP
at a dose of 20 mg/kg, 24 hours after Lip-CLOD administration.
The inhibition of tumor growth induced by LCL-PLP and free
PLP was analyzed using area under tumor growth curve (AUTC) un-
til day 14 after tumor cell inoculation. The results are shown in Fig-
ure 3, A and B. Tumor volume results at day 14 are also shown in
Figure 3, C and D. Both with and without Lip-CLOD pretreatment,
empty liposomes as well as free PLP did not have a statistically sig-
nificant antitumor effect compared to PBS. In line with the results
shown in Figure 2, Lip-CLOD pretreatment inhibited tumor growth
in both PBS- and empty liposome–treated groups (Figure 3, B and D
compared with A and C ). When the Lip-CLOD pretreatment was
not given, LCL-PLP inhibited tumor growth by 83% (P < .05) com-
pared to PBS treatment (Figure 3, A and C ). In the case of LCL-PLP
treatment, AUTC values and tumor volumes after Lip-CLOD pre-
treatment were not significantly different from those without Lip-
CLOD pretreatment (Figure 3, B and D compared with A and C ).
It is likely, however, that in the Lip-CLOD–pretreated groups, the
antitumor effect of LCL-PLP treatment is overshadowed by the pre-
treatment effect.
Effect of Lip-CLOD Treatment on the Production of
Angiogenic Proteins In Vivo
To investigate whether TAM are an important source of angiogenic
factors in tumors, B16.F10 melanoma-bearing mice were injected i.v.
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with Lip-CLOD at a dose of 25 mg/kg at day 7 after tumor cell
inoculation. On day 12, the mice were sacrificed, tumors were iso-
lated, and angiogenic protein levels in tumor tissue were determined
by using an angiogenic protein array (RayBio Mouse Angiogenic pro-
tein Antibody Array membranes 1.1; RayBiotech Inc.) [12]. Lip-
CLOD treatment reduced the level of most of the pro-angiogenic
factors by 35% (P = .0001) compared to the levels in control tumors
(i.e., in mice not treated with Lip-CLOD) (Table 3; Figure 4, column
A). More specifically, Lip-CLOD reduced the level of granulocyte–
macrophage–colony-stimulating factor (GM-CSF), interleukin
(IL)-6, IL-9, Fas ligand (FasL), basic fibroblast growth factor
(bFGF), and thrombopoietin (TPO) by 25% to 50%, granulo-
cyte–colony-stimulating factor (G-CSF), IL-1α, IL-1β, tumor necro-
sis factor (TNF) α, monocyte chemoattractant protein-1 (MCP1) by
50% to 75%, and leptin by 95%. Interestingly, Lip-CLOD treatment
also strongly reduced the production of two anti-angiogenic factors
[tissue inhibitor of metalloproteinase (TIMP)-1 and -2] (Table 4; Fig-
ure 4, column A). This inhibitory effect on angiogenic factor produc-
tion induced by Lip-CLOD demonstrates the important role of TAM
in production of these factors in B16.F10 melanoma.
Figure 1. Immunohistochemical analysis of the macrophage antigen F4/80 in B16.F10 melanoma tumor sections from mice treated
with Lip-CLOD. Red stain indicates areas with infiltrated TAM in tumor tissue. Sections were counterstained with hematoxylin. Tumor-
associated macrophage distribution in tumor tissue was verified at 48 and 96 hours after Lip-CLOD administration. (A) Lip-CLOD treatment
(48 hours): tumors do not contain TAM. (B) PBS treatment at the same time point: TAM at the rim of the tumors. (C) Lip-CLOD treatment
(96 hours): tumors show similar dispersion of TAM in large areas but containing TAM at a lower density compared to TAM in control tumors.
(D) PBS treatment at the same time point: tumors show large areas with TAM infiltrated in tumor tissue. Control tumors are tumors from
mice not treated with Lip-CLOD but treated with PBS (B and D). Left panels were magnified 10 and right panels were magnified 40×.
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Effect of Pretreatment with Lip-CLOD on the Inhibitory
Action of LCL-PLP on Tumor Angiogenesis
To assess the effects of the treatment with LCL-PLP and free PLP
on the production of angiogenic factors by TAM in s.c. B16.F10
melanoma tumors, mice were pretreated with Lip-CLOD. Subse-
quently, LCL-PLP and free PLP were administered i.v. 20 mg/kg
at days 8 and 11 after tumor cell inoculation. On day 12, mice were
sacrificed, tumors were isolated, and angiogenic protein levels in tu-
mor tissue were screened. No changes were observed between angio-
genic protein levels in tumors from mice treated with PBS and empty
liposomes (data not shown). In case of treatment with LCL-PLP and
free PLP, however, changes were observed.
In the absence of Lip-CLOD pretreatment, both LCL-PLP and
free PLP reduced the level of the majority of pro-angiogenic factors
compared to control treatment (Table 1). For 10 of 17 pro-angiogenic
proteins studied, reduction was significantly stronger after treatment
with LCL-PLP than after free PLP (Table 1). LCL-PLP treatment sup-
pressed expression of the pro-angiogenic factors GM-CSF, M-CSF, IL-
1α, IL-1β, IL-6, IL-9, interleukin 12 p40 (IL-12 p40), TNF α,
MCP1, and FasL (by 50–75%) and G-CSF, bFGF, leptin, and eotaxin
(by 75–100%).
The level of the majority of anti-angiogenic proteins was not or only
slightly suppressed by LCL-PLP and free PLP treatments (Table 2) ex-
cept for the levels of the anti-angiogenic factors interferon γ (IFN-γ)
and monokine induced by IFN-γ (MIG) which dropped strongly after
LCL-PLP treatment (by 55–65%) (Table 2).
Figure 2. Effect of Lip-CLOD treatment on growth of s.c. B16.F10
melanoma. Tumor volumes at day 14 (the day when the first tu-
mors from the control group reached a volume of 2 cm3) were
compared to volumes of control tumors at the same time point.
Control tumors are tumors from mice not treated with Lip-CLOD
but treated with PBS. Student's t test for comparison of tumor
volumes was used. P = .02. The results represent mean ± SD
of five mice. Control, treatment with PBS; Lip-CLOD, treatment
with Lip-CLOD.
Figure 3. Effect of Lip-CLOD pretreatment on the antitumor activity of LCL-PLP. Tumor growth for each experimental group is analyzed
using AUTC until day 14 (the day when the first tumors from the control group reached a volume of 2 cm3). Panels A and B show AUTCs
by day 14. (A) Only LCL-PLP treatment. (B) Lip-CLOD pretreatment given before LCL-PLP treatment. Panels C and D show tumor volume
at day 14. (C) Only LCL-PLP treatment. (D) Lip-CLOD pretreatment given before LCL-PLP treatment. The results are compared to PBS-
treated groups. One-way ANOVA with Dunnett multiple comparison test was used; ns, not significant (P> .05); *P< .05; **P< .01. The
results represent mean ± SD of five mice. AUTC, area under the tumor growth curve;−Lip-CLOD, no pretreatment with Lip-CLOD;+Lip-
CLOD, pretreatment with Lip-CLOD; PBS, treatment with PBS; LCL, treatment with empty LCL; Free PLP, treatment with free PLP; LCL-
PLP, treatment with LCL-PLP.
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In case of Lip-CLOD pretreatment, LCL-PLP only strengthened
the reducing effect of Lip-CLOD on the pro-angiogenic protein lev-
els, by about 20% (P = .0001) (Table 3; Figure 4, column A com-
pared to column C ). The reducing effects of LCL-PLP treatment
on the production anti-angiogenic factors in tumors was dominated
by the effect of Lip-CLOD administration (Table 4; Figure 4, column
A compared to column C ).
Immunohistochemical Examination of Tumor Tissue
To compare the effects of LCL-PLP treatment with and without
Lip-CLOD pretreatment on TAM infiltration, we evaluated macro-
phage antigen F4/80–stained sections of B16.F10 melanoma by light
microscopy (Table 5). LCL-PLP were injected i.v. at a dose of 20 mg/
kg 24 hours after Lip-CLOD pretreatment. Tumors were dissected
48 and 96 hours after Lip-CLOD administration. Immunohisto-
chemical analysis for the macrophage antigen F4/80 showed different
patterns of TAM distribution in tumor sections (Figures 1 and 5;
Table 5). At 48 hours, in all groups receiving treatment with Lip-
CLOD, TAMs were hardly present in tumor tissue (Figure 1A; Ta-
ble 5), whereas in control tumors, large areas with TAM at the rim of
the tumors were observed (Figure 1B). Interestingly, at this time point,
small groups of TAM were seen in tumors from animals treated only
with LCL-PLP (Figure 5A; Table 5). At 96 hours, TAMs were present
in large areas spread over the tumor tissue in control tumors (Fig-
ure 1D; Table 5). After treatment with Lip-CLOD, tumors show sim-
ilar dispersion of TAM in large areas but containing TAM at a lower
density compared to TAM in control tumors (Figure 1C; Table 5). At
Figure 4. Effect of Lip-CLOD pretreatment on antiangiogenic activity of LCL-PLP. Results presented as % reduction of tumor angiogenic
factors ranging from 0% (white) to 100% (black) compared to levels of angiogenic factors in control tumors (tumors in mice treated with
PBS and not treated with Lip-CLOD). (Column A) Lip-CLOD, treatment with Lip-CLOD. (Column B) LCL-PLP, treatment with LCL-PLP.
(Column C) Lip-CLOD + LCL-PLP, pretreatment with Lip-CLOD followed by LCL-PLP treatment.
Table 1. Effects of i.v. Administered LCL-PLP and Free PLP on Pro-angiogenic Protein Levels in
s.c. B16.F10 Tumors When Lip-CLOD Pretreatment Was Not Given.
Pro-angiogenic
Factors
Reduction Induced By
LCL-PLP (% of Reduction
as Mean ± SD)
Reduction Induced By
Free PLP (% of Reduction
as Mean ± SD)
Statistical
Differences
G-CSF 82.5 ± 3.6 42.6 ± 11.4 *
GM-CSF 59.4 ± 5.2 23.3 ± 16.0 *
M-CSF 60.0 ± 3.0 19.3 ± 12.6 *
IGF-II 41.3 ± 5.3 21.0 ± 29.8 NS
IL-1α 63.3 ± 8.5 29.5 ± 13.2 †
IL-1β 63.5 ± 10.0 15.0 ± 11.0 †
IL-6 74.5 ± 9.6 31.0 ± 2.7 *
IL-9 61.5 ± 24.0 19.2 ± 5.4 ‡
IL-12 p40 58.5 ± 7.3 29.5 ± 3.5 NS
TNF α 65.2 ± 0.3 25.0 ± 22.0 ‡
MCP1 70.5 ± 18.7 4.0 ± 5.0 NS
Eotaxin 100.00 ± 0.00 97.4 ± 3.7 NS
FasL 61.4 ± 3.5 26.7 ± 2.7 NS
bFGF 79.6 ± 10.5 24.2 ± 10.2 ‡
VEGF 0.00 ± 0.00 0.00 ± 0.00 NS
Leptin 78.4 ± 23.4 13.0 ± 3.0 ‡
TPO 22.4 ± 9.7 10.5 ± 8.3 NS
Pro-angiogenic factors are defined as proteins reported in the literature to favor angiogenesis and
tumor-associated inflammation. The protein levels are compared to protein levels in control tumors.
The results were analyzed for statistically significant differences between the effects of different
treatments on the levels of pro-angiogenic factors. A two-way ANOVA with Bonferroni correction
for multiple comparisons was used and the P values are indicated as follows: NS, not significant
(P > .05); *P < .05; †P < .01; ‡P < .001.
The results represent the mean ± SD of two independent experiments.
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96 hours after Lip-CLOD pretreatment, TAM were grouped in small
areas in the tumor tissue from LCL-PLP–treated mice (Table 5). In-
terestingly, after treatment with LCL-PLP only, tumors showed the
same distribution of TAM in small clusters in tumor tissue as observed
at the 48-hour observation time point (Figure 5B; Table 5).
Discussion
The present study provides confirmatory evidence for an anti-
angiogenic/antiinflammatory mode of antitumor action of LCL-PLP
through the suppressive effects on TAM functions. Our previous ob-
servations on intratumoral accumulation of LCL in the endosomal/
lysosomal compartment of TAM pointed to a route for therapeutic
intervention using LCL-PLP [2]. Tumor-associated macrophages play
a crucial role in tumor growth being actively involved in promoting
the angiogenic switch as well as in the maintenance of tumor angio-
genesis [15]. Tumor-associated macrophages are an important source
of inflammatory and angiogenic factors, such as TNF α, IL-8, IL-1β,
IL-6, VEGF, and bFGF, proteases present in tumors, such as matrix
metalloproteinases (MMPs), urokinase plasminogen activator, and
plasmin [4,16–20]. To evaluate whether TAMs play a crucial role in
B16.F10 melanoma growth, tumor-bearing mice were treated with
Lip-CLOD due to their ability to deplete macrophages [13]. Previous
studies already showed the feasibility of clodronate encapsulated in li-
posomes for elimination of TAM from s.c. tumor tissue [21]. Our re-
sults show that i.v. administered Lip-CLOD inhibited tumor growth
by approximately 55% compared to tumor growth in control animals
(Figure 2). Furthermore, Lip-CLOD induced a moderate to strong
reduction of the intratumoral production of the majority of the pro-
angiogenic factors (Figure 4, column A; Table 3). These antitumor
effects induced by Lip-CLOD demonstrate the role of TAM in sup-
porting the growth of B16.F10 melanoma through the production of
the pro-angiogenic factors. Most of the pro-angiogenic factors pro-
duced by TAM (e.g., G-CSF, GM-CSF, IL-1α, IL-1β, IL-6, IL-9,
TNF α, and MCP1) also have pro-inflammatory effects involved in
tumor growth [22–31]. Tumor angiogenesis and tumor inflammation
are interconnected and TAM are able to drive both processes making
them central forces in tumor growth and expansion [32].
A particular finding was that Lip-CLOD treatment strongly re-
duced the tumor levels of two anti-angiogenic factors TIMP-1 and
TIMP-2 (Figure 4, column A; Table 4). Besides tumor growth pro-
moting effects, TAM exert antitumor effects through the production
of these anti-angiogenic factors. It is known that TIMPs produced by
TAM and fibroblasts can inhibit the tumorigenic and metastatic phe-
notype of cancer cells [33–36]. Several studies support the hypothesis
of a dual role of TAM in tumor growth [5,16,37].
Taken together, the results obtained with Lip-CLOD treatment sug-
gest that TAM are an important source of pro-angiogenic factors as well
as of certain anti-angiogenic factors (Figure 4, column A; Tables 3 and 4).
To further study the earlier suggested role of TAM in the mode of
antitumor action of LCL-PLP [1], we investigated the effects of pre-
treatment with Lip-CLOD on the antitumor activity of LCL-PLP. In
line with previous results [1,2], when Lip-CLOD pretreatment was not
Table 2. Effects of i.v. Administered LCL-PLP and Free PLP on Anti-angiogenic Protein Levels in
s.c. B16.F10 Tumors When Lip-CLOD Pretreatment Was Not Given.
Anti-angiogenic
Factors
Reduction Induced By
LCL-PLP (% of Reduction
as Mean ± SD)
Reduction Induced By
Free PLP (% of Reduction
as Mean ± SD)
Statistical
Differences
TIMP-1 0.2 ± 0.3 0.0 ± 0.0 NS
TIMP-2 12.4 ± 3.2 16.3 ± 7.0 NS
PF4 22.6 ± 3.2 13.6 ± 13.3 NS
IL-12 p70 11.6 ± 11.3 13.5 ± 12.3 NS
IL-13 38.3 ± 8.7 17.3 ± 0.6 NS
IFN-γ 65.2 ± 12.5 10.1 ± 0.2 *
MIG 54.2 ± 8.7 37.0 ± 11.2 NS
The anti-angiogenic factors are defined as proteins reported in the literature to impede angiogen-
esis and tumor-associated inflammation. The protein levels are compared to protein levels in con-
trol tumors.
The results were analyzed for statistically significant differences between the effects of different
treatments on the levels of anti-angiogenic factors. A two-way ANOVA with Bonferroni correction
for multiple comparisons was used and the P values are indicated as follows: NS, not significant
(P > .05); *P < .001.
The results represent the mean ± SD of two independent experiments.
Table 3. Effects of i.v. Administered Lip-CLOD and LCL-PLP on Pro-angiogenic Protein Levels in
s.c. B16.F10 Tumors.
Pro-angiogenic
Factors
Reduction Induced
By Lip-CLOD +
LCL-PLP (% of
Reduction as Mean ± SD)
Reduction Induced
By Lip-CLOD (% of
Reduction as Mean ± SD)
Statistical
Differences
G-CSF 73.8 ± 13.3 52.3 ± 20.7 NS
GM-CSF 56.5 ± 16.2 36.4 ± 7.0 NS
M-CSF 52.8 ± 23.6 19.7 ± 13.3 NS
IGF-II 41.8 ± 16.1 6.0 ± 8.4 NS
IL-1α 64.0 ± 17.6 53.0 ± 13.8 NS
IL-1β 60.1 ± 6.3 59.4 ± 20.4 NS
IL-6 60.8 ± 19.6 49.7 ± 8.0 NS
IL-9 59.5 ± 16.5 48.4 ± 3.5 NS
IL-12 p40 37.0 ± 48.2 19.1 ± 25.0 NS
TNF α 59.4 ± 3.0 53.0 ± 6.6 NS
MCP1 73.1 ± 11.0 59.4 ± 3.6 NS
Eotaxin 98.4 ± 0.5 62.4 ± 2.8 NS
FasL 61.1 ± 6.5 30.6 ± 8.2 NS
bFGF 92.1 ± 3.9 36.3 ± 24.0 *
VEGF 0.0 ± 0.0 0.0 ± 0.0 NS
Leptin 87.7 ± 17.5 94.5 ± 3.6 NS
TPO 43.5 ± 2.2 37.7 ± 2.7 NS
The protein levels are compared to protein levels in control tumors, which were not treated
with Lip-CLOD.
The results were analyzed for statistically significant differences between the effects of different
treatments on the levels of pro-angiogenic factors. A two-way ANOVA with Bonferroni correction
for multiple comparisons was used and the P values are indicated as follows: NS, not significant
(P > .05); *P < .01.
The results represent the mean ± SD of two independent experiments.
Table 4. Effects of i.v. Administered Lip-CLOD and LCL-PLP on Anti-angiogenic Protein Levels
in s.c. B16.F10 Tumors.
Anti-angiogenic
Factors
Reduction Induced
By Lip-CLOD +
LCL-PLP (% of
Reduction as Mean ± SD)
Reduction Induced
By Lip-CLOD (% of
Reduction as Mean ± SD)
Statistical
Differences
TIMP-1 68.0 ± 12.0 62.0 ± 12.0 NS
TIMP-2 100.0 ± 0.0 100.0 ± 0.0 NS
PF4 9.4 ± 11.1 9.7 ± 13.7 NS
IL-12 p70 20.8 ± 0.8 19.7 ± 10.8 NS
IL-13 43.7 ± 24.5 23.1 ± 32.7 NS
IFN-γ 77.8 ± 2.6 3.0 ± 4.1 *
MIG 52.4 ± 0.3 27.0 ± 3.0 NS
The protein levels are compared to protein levels in control tumors which were not treated
with Lip-CLOD.
The results were analyzed for statistically significant differences between the effects of different
treatments on the levels of anti-angiogenic factors. A two-way ANOVA with Bonferroni correction
for multiple comparisons was used and the P values are indicated as follows: NS, not significant
(P > .05); *P < .001.
The results represent the mean ± SD of two independent experiments.
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given, LCL-PLP strongly inhibited tumor growth compared to the
growth of control tumors (Figure 3, A and C ). However, when B16.
F10 melanoma-bearing mice were pretreated with Lip-CLOD, no ad-
ditional inhibitory effect of LCL-PLP on tumor growth was noted (Fig-
ure 3, B and D). This is obviously due to the overshadowing effect of
Lip-CLOD pretreatment, indicating that the antitumor activity of
LCL-PLP depends on the presence of functional TAM in the tumor.
The antitumor effects of LCL-PLP are likely primarily caused by their
suppressive effects on the TAM-mediated production of pro-angiogenic
factors in tumors. Without Lip-CLOD pretreatment, LCL-PLP exerts a
strong reducing effect on the level of most of the pro-angiogenic factors.
Notably, LCL-PLP reduced strongly the production of following key
factors responsible for the regulation of TAM functions, such as GM-
CSF, M-CSF, G-CSF, and MCP1. These factors are involved in attract-
ing new monocytes from the bloodstream into the tumor tissue and
stimulating these newly recruited tumor macrophages to produce pro-
angiogenic factors [16,38,39]. The suppressive effect of LCL-PLP on
TAM-mediated production of pro-angiogenic factors in tumors is sup-
ported by the immunohistochemical observations. The microscopic
images of F4/80–stained tumor sections show that in tumors from mice
treated with LCL-PLP, TAMs are inactivated or unable to infiltrate the
tumor tissue, leading to their clustering in small spots (Figure 5, A and
B; Table 5). Likely, the impaired macrophage infiltration in tumor
tissue is a reflection of the reduced capability of TAM to produce
pro-angiogenic proteins, due to the treatment with LCL-PLP, as these
factors are also responsible for chemoattraction and spreading of macro-
phages in tumor tissue [16,38,39].
Notably, production of VEGF, a key pro-angiogenic factor, was not
affected by LCL-PLP and Lip-CLOD treatments. Both the TAM-
suppressive formulations, LCL-PLP and Lip-CLOD, did not show
Table 5. Effects of LCL-PLP Treatment on TAM Dispersion in B16.F10 Melanoma Tumors Visualized After F4/80 Immunostaining.
Time Point (h) TAM Distribution Without Lip-CLOD Lip-CLOD Lip-CLOD + Free PLP Lip-CLOD + LCL-PLP
PBS Free PLP LCL-PLP
48 Density (+ few, ++ normal, +++ many TAM) ++ + ++ + + +
Mainly in rim *
Spread over the tumor tissue in large areas
Grouped in tumor tissue in small areas * *
96 Density (+ few, ++ normal, +++ many TAM) +++ +++ + ++ ++ +
Mainly in rim
Spread in tumor tissue in large areas * * * *
Grouped in tumor tissue in small areas * *
* indicates the presence of TAM.
Figure 5. Immunohistochemical analysis of the macrophage antigen F4/80 in B16.F10 melanoma tumor sections from mice treated with
LCL-PLP treatment. Red stain indicates areas with infiltrated macrophages in tumor tissue. Sections were counterstained with hema-
toxylin. Macrophage distribution in tumor tissue was verified at 48 and 96 hours after Lip-CLOD administration. (A) (48 hours) LCL-PLP
treatment without Lip-CLOD pretreatment: small areas with macrophages. At this time point, tumor sections from mice pretreated with
Lip-CLOD followed by LCL-PLP treatment do not show macrophages (data not shown). (B) (96 hours) LCL-PLP without Lip-CLOD pre-
treatment: small areas with macrophages. The same pattern of macrophage distribution was noted in tumors from mice pretreated with
Lip-CLOD followed by LCL-PLP treatment (data not shown). Left panels were magnified 10× and right panels were magnified 40×.
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this reducing effect on VEGF, supporting that TAM are not mainly
involved in production of this factor in melanoma tumor tissue. In
line with this observation, several studies showed that VEGF is pro-
duced in high amounts by melanoma cells [5].
In tumors from mice which were not pretreated with Lip-CLOD,
the production of anti-angiogenic/anti-inflammatory factors was only
slightly affected by LCL-PLP. In our study, only the anti-angiogenic
factors IFN-γ and MIG showed a strong decrease in tumor level after
LCL-PLP treatment (Figure 4, column B; Table 2). The expression of
these two factors may suffer from suppressive effects of LCL-PLP on
cells other than TAM, such as natural killer (NK)-cells (for IFN-γ),
fibroblasts, and endothelial cells (for MIG) [40–42]. Interestingly,
LCL-PLP treatment did not affect the TAM-mediated production
of TIMP-1 and TIMP-2 whereas the production of these two anti-
angiogenic factors was drastically reduced after TAM suppression in-
duced by Lip-CLOD pretreatment (Figure 4, column B compared to
column A; Tables 2 and 4). This remarkable observation may relate to
studies demonstrating a stimulatory effect of prednisolone on TIMP
production in patients with chronic bronchitis [43].
When Lip-CLOD pretreatment was administered, LCL-PLP only
slightly strengthened the reducing effect of Lip-CLOD pretreatment
on the tumor levels of pro-angiogenic proteins as the inhibitory effect
of LCL-PLP on tumor angiogenesis depends on the presence of func-
tional TAM in the tumor. These results are in line with the critical
role of functional TAM in supporting tumor angiogenesis and in-
flammation through production of pro-angiogenic/pro-inflammatory
factors [4,32]. Apparently, LCL-PLP have little effects on other cell
types in the tumor than TAM, such as fibroblasts, endothelial cells,
and NK cells [22,25,42,44].
Taken together, our studies indicate that TAMs play a vital role
in coordinating tumor growth being an important source of pro-
angiogenic/pro-inflammatory factors involved in all steps in tumor
angiogenesis. One of the major inhibitory actions of LCL-PLP on
tumors is based on the reduction of the TAM-mediated production of
pro-angiogenic factors, whereas production of anti-angiogenic factors
by these cells is hardly affected. LCL-PLP are likely not to induce
strong effects on other cell types present in the tumor tissue than
TAM, such as fibroblasts, endothelial cells, and NK cells.
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